Last week the pharmaceutical company Merck released promising early data on a pill for Covid-19, which trials suggest halves hospitalisations and deaths. So what do we know about this experimental treatment? Madeleine Finlay talks to the Guardian’s science correspondent Hannah Devlin about whether this antiviral could be a gamechanger. And as some UK experts warn ‘ there isn’t much A&E capacity left’, we also hear from Prof Peter Horby on the importance of drugs in the fight against Covid-19. Help support our independent journalism at <a href="https://www.theguardian.com/sciencepod">theguardian.com/sciencepod</a>
